Drug Profile
Onvatilimab - Immunext
Alternative Names: anti-VISTA antibody; CI 8993; JNJ 61610588Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator ImmuNext
- Developer Curis; ImmuNext; Janssen Research & Development
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Jan 2024 Option and license agreement between Curis and ImmuNext expires for VISTA antagonizing compounds, including CI 8993 in January 2024
- 19 May 2023 Curis completes a phase I trial in Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia and USA (IV) (NCT04475523)
- 31 Dec 2022 Immunext has patent protection for anti-VISTA antibodies including onvatilimab in USA